Padmaja, S. and Naveen, G. (2021) A Review on Acotiamide. Journal of Pharmaceutical Research International, 33 (56A). pp. 127-129. ISSN 2456-9119
![[thumbnail of 4664-Article Text-6751-1-10-20221006.pdf]](http://articles.sendtopublish.com/style/images/fileicons/text.png)
4664-Article Text-6751-1-10-20221006.pdf - Published Version
Download (388kB)
Official URL: https://doi.org/10.9734/jpri/2021/v33i56A33894
Abstract
Functional dyspepsia (FD) is mainly treated by drugs like H2 receptors antagonists, Proton pump inhibitors, prokinetics. A novel prokinetic drug to treat FD with 2 subtypes: Epigastric pain syndrome (EPS) & postprandial distress syndrome (PDS), has been introduced recently by the approval of Acotiamide, the first in class, muscarinic receptor antagonist & cholinesterase inhibitor. It has shown improvement in gastric motility in rodents & dogs and reduced PDS symptoms in patients in Double- blinded multicentric study.
Item Type: | Article |
---|---|
Subjects: | Open STM Article > Medical Science |
Depositing User: | Unnamed user with email support@openstmarticle.com |
Date Deposited: | 07 Apr 2023 08:11 |
Last Modified: | 04 Jun 2025 03:49 |
URI: | http://articles.sendtopublish.com/id/eprint/117 |